Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.32% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
RKDA · Dec 31, 2024
Arcadia Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-25-044487General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-190.82% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-5.35% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
17.92% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
41.27% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-72.31% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
1.05% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
10.15% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History19 statesSelf-history eligible
Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/8 normalizedLevel 3Dec 31, 20220/8 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20230/8 normalizedLevel 3Sep 30, 20236/8 normalizedLevel 3Dec 31, 20237/8 normalizedLevel 3Mar 31, 20247/8 normalizedLevel 3Jun 30, 20247/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 0.00%
- Current
- 0.32%
- Delta
- 0.32%
- Previous
- -113.99%
- Current
- -190.82%
- Delta
- -76.83%
- Previous
- -3.76%
- Current
- -5.35%
- Delta
- -1.59%
- Previous
- 54.33%
- Current
- 17.92%
- Delta
- -36.41%
- Previous
- 32.86%
- Current
- 41.27%
- Delta
- 8.41%
- Previous
- -114.51%
- Current
- -72.31%
- Delta
- 42.20%
- Previous
- 1.56%
- Current
- 1.05%
- Delta
- -0.51%
- Previous
- 10.08%
- Current
- 10.15%
- Delta
- 0.06%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · RKDA Fundamental State →Has State · Arcadia Biosciences, Inc. →Transitioned To · RKDA historical state 2024-09-30 →Transitioned To · RKDA CAPEX_INTENSITY_INCREASED →Transitioned To · RKDA CASH_GENERATION_DECREASED →Transitioned To · RKDA GROWTH_DECREASED →Transitioned To · RKDA INVENTORY_PRESSURE_DECREASED →Transitioned To · RKDA MARGIN_INCREASED →Transitioned To · RKDA PROFITABILITY_INCREASED →Transitioned To · RKDA R_AND_D_INTENSITY_DECREASED →Transitioned To · RKDA SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.